Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.
Company profile
Ticker
ANTH
Exchange
Website
CEO
John Craig Thompson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
201852016
Latest filings (excl ownership)
15-12B
Securities registration termination
30 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
EFFECT
Notice of effectiveness
27 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 18
Latest ownership filings
3
Mark Drew McManigle
12 Sep 18
SC 13G/A
Anthera Pharmaceuticals Inc
22 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
14 Feb 18
SC 13G/A
Anthera Pharmaceuticals Inc
5 Feb 18
SC 13G
Anthera Pharmaceuticals Inc
18 Jan 18
4
CHRISTOPHER S HENNEY
9 Jan 18
4
PAUL F TRUEX
9 Jan 18
4
Brent Furse
9 Jan 18
4
MAY LIU
9 Jan 18
Institutional ownership, Q4 2019
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Verus Capital Partners | 2.00 k | $0.00 |